EIPICO, Egypt’s pharmaceutical powerhouse, delivered explosive growth in Q1-24. Consolidated net profit skyrocketed to EGP 603.62 million, a staggering 217% leap from EGP 188.41 million in Q1-23. Net sales surged 51% year-on-year to EGP 1.50 billion, reflecting robust demand. Standalone performance mirrored this success: net profit jumped 243% to EGP 626.14 million, with revenues hitting EGP 1.44 billion. Earnings per share (EPS) tripled to EGP 5.15, signaling strong investor returns. The company also reported a 28% annual profit increase in 2023, cementing its growth trajectory.